The DDR inhibitor VX-970 (ATR inhibitor) sensitizes cancer cells to the combination of CarboPt and the anticancer drug gemcitabine [154], which generates ROS by NOX and via NF-κB activation in diverse cancer types (http://clinicaltrials.gov identifier: NCT02627443). This evidence concerns the gene ATR and cancer.